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Purpose: Anaplastic thyroid cancer is known to have a poor prognosis due to its 
aggressive and rapid metastasis with median survival of less than 6 months. Multi-
modal treatment involving surgery and chemoradiotherapy has been used to im-
prove the survival of patients. Here, we retrospectively review of treatment out-
come of 13 consecutive patients who were treated at a single center. Materials 
and Methods: We retrospectively reviewed medical records of 13 anaplastic thy-
roid cancer patients who received multidisciplinary treatment between 2006 and 
2010. Kaplan-Meier survival curve was used to analyze progression-free survival 
and overall survival of patients. Results: The median patient age at diagnosis was 
69 years, and six patients had stage IVc diseases. Eight patients received primary 
surgery followed by radiotherapy or concurrent chemoradiotherapy (CCRT). Five 
patients received weekly doxorubicin-based definitive CCRT, but only one pa-
tient’s condition remained stable, while the rest experienced rapid disease progres-
sion. The median progression-free survival was 2.8 months (95% CI, 1.2-4.4 
months), and the median overall survival was 3.8 months (95% CI, 3.0-4.6 
months). Conclusion: Patients with anaplastic thyroid cancer showed poor prog-
nosis despite multimodality treatment. Therefore, identification of novel therapeu-
tic targets is warranted to take an effective mode of treatment.
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INTRODUCTION
Anaplastic thyroid cancer (ATC) is a rare disease, accounting for 1.6% of all thy-
roid cancers. It is known to be the most lethal among all thyroid cancers, and the 
median life expectancy is about 4 months.1,2 Due to its dismal prognosis, there 
have been different kinds of treatment modalities to improve patient survival. The 
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resonance imaging (MRI). The staging of the tumors was 
done according to the 2002 (sixth edition) Union Internatio-
nale Contre le Cancer/American Joint Committee on Can-
cer TNM system.11 This study was approved by the Institu-
tional Review Board of Severance Hospital.
　　　　
Chemoradiotherapy
Patients were administered with 10 mg/m2 doxorubicin week-
ly, concurrently with radiotherapy. Patients were required to 
have an absolute neutrophil count ≥1500/μL without evi-
dence of active infection and platelet count ≥100000/μL. A 
dose reduction of doxorubicin to 10% was prescribed in 
cases of febrile neutropenia and grade 3 or more chemo-
therapy-related non-hematologic toxicity. Antiemetic thera-
py was routinely given before chemotherapy. Granulocyte-
colony stimulating factor was not provided for prophylactic 
purposes. 
For 3-dimensional conformal radiotherapy, the definitive 
curative radiation dose to the primary tumor was 70 Gy, de-
livered in single daily fractions of 2.0 Gy for 5 days a week. 
Involved lymph nodes were to receive 63 to 70 Gy, and the 
dose administered to uninvolved lymph nodes were 45-54 
Gy. All patients underwent dental evaluation and treatment 
as soon as possible before the initiation of radiotherapy.
Surgery
Surgical therapy for ATC included radical resection for pa-
tients with resectable tumors, palliative resection for tumor 
debulking purposes, and excisional biopsy only for unre-
sectable cases. R0 resection indicated complete resection 
with no microscopic residual tumor. Residual disease at the 
resection margin was divided into microscopic (R1) resec-
tion and macroscopic (R2) resection.12
Evaluation of response and toxicity
Each patient underwent baseline evaluations, including a 
complete physical examination, CT and/or MRI of the target 
lesion. Tumor response was evaluated by clinical examina-
tion, neck CT scan or MRI 4 to 6 weeks after chemoradio-
therapy, and at follow-up visits until disease progression. Pa-
tients were followed by imaging study with CT scan or MRI 
every three months. Based on the Response Evaluation Cri-
teria in Solid Tumor criteria, responses were assessed and 
categorized as complete response, partial response, stable 
disease, and progressive disease. Complete response was 
defined as complete disappearance of all measurable disease 
for a duration of at least 4 weeks, and partial response (PR) 
first treatment option is to perform palliative surgeries of 
thyroid cancer to reduce the tumor burden. However, many 
patients present with an inoperable disease, and complete 
resection is possible for only up to one-third of patients at 
presentation.3 After the surgery, either radiotherapy or che-
motherapy or both could be provided to prevent tumor pro-
gression and further distant metastasis.4 
Weekly administration of low-dose doxorubicin concur-
rently with radiation therapy showed an acceptable toxicity 
and may be a therapeutic option for patients with ATC.5,6 
The 2-year local control rate is 68%, and the median sur-
vival time is 1 year.6 Combination chemotherapy with bleo-
mycin, doxorubicin, and cisplatin resulted in response rate 
of 40% in advanced thyroid cancer, producing considerable 
palliative effects.7 It is noteworthy that best responses to 
this regimen were observed often in patients with ATC. There 
are increasing interests in the use of taxanes for ATC, with 
an overall response rate of 53% in advanced ATC patients 
who were treated with a 96-hour infusion of paclitaxel.8 
In addition to chemotherapy, radiotherapy may help im-
prove survival depending on the extent of disease. Postop-
erative radiotherapy improved survival of patients with dis-
ease extending to adjacent tissue, but it does not provide 
much benefit for patients with further extended disease or 
distant metastasis.9 Compared with once-daily regimen, a 
twice-daily fractionation regimen was well tolerated and 
showed a trend toward improved survival (13.6 months vs. 
10.3 months in patients treated with once-daily fraction-
ation). Moreover, the 6-month local progression-free rate in 
patients who underwent radical radiotherapy was 94.1%, 
which was significantly higher compared with palliative ra-
diotherapy (64.6%). The median overall survival was lon-
ger with radical radiotherapy (11.1 months) compared with 
palliative radiotherapy (3.2 months).10
In this study, we retrospectively reviewed 13 ATC pa-
tients who received multidisciplinary treatment at the Yon-
sei Cancer Center between 2006 and 2010. 
MATERIALS AND METHODS
　　　
We identified ATC patients who received multimodality 
treatment, based on the cancer registry data of the Yonsei 
Cancer Center from 2006 to 2010. Medical records of all 
patients were retrospectively reviewed. Initially, patients 
were examined by laboratory tests and imaging studies, in-
cluding neck computed tomography (CT) or neck magnetic 
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as 30% decrease at least in the sum of diameters of target 
lesions. Progressive disease (PD) is  20% increase at least 
in the sum of diameters of target lesions and an absolute in-
crease by at least 5 mm. Stable disease was defined as nei-
ther sufficient shrinkage to qualify for PR nor sufficient in-
crease to qualify for PD.13 Toxicity was recorded according 
to the National Cancer Institute Common Toxicity Criteria 
(version 2.0). 
　　　　
Statistical analysis
The SPSS statistical package was used for statistical analy-
sis. Local recurrence was defined as tumor recurrence in the 
neck. Recurrences at other sites were scored as distant me-
tastases. Progression-free survival was defined as the time 
from the first day of therapy until first disease progression, 
death, or death from any cause. Overall survival was de-
fined as the time from the first day to the date of death from 
any cause. Survival curves were estimated using the Ka-
plan-Meier method.
 
RESULTS
 
Table 1 summarizes patient characteristics. The median pa-
tient’s age at diagnosis was 69 years, and there were 4 men 
and 9 women. The majority of patients had Eastern Coop-
erative Oncology Group (ECOG) PS 1. Most patients 
(54%) presented with unresectable primary tumors (T4b) 
with the median size of 9 cm (range, 3-12 cm) and regional 
nodal involvement (N1). The size of the primary tumor av-
eraged 9 cm (range, 3-12 cm). Six patients (46%) had dis-
tant metastasis (IVc) at diagnosis. The most common site of 
distant metastasis was the mediastinum followed by the 
lung. Five patients received doxorubicin-based definitive 
concurrent chemoradiotherapy (CCRT), and eight received 
surgery followed by postoperative RT or CCRT. Palliative 
surgery was performed in four patients with unresectable 
primary tumors in order to relieve local symptoms from a 
large neck mass or impending tracheal obstruction.
Fig. 1 shows the Kaplan-Meier curve of progression-free 
survival (dotted line) and overall survival (black line) of all 
patients. The median progression-free survival and overall 
survival were 2.8 months (95% CI, 1.2-4.4 months) and 3.8 
months (95% CI, 3.0-4.6 months), respectively. 
Table 2 shows the treatment outcomes of five patients 
who were treated with definitive doxorubicin-based CCRT 
as an initial therapy for primary tumor. One patient re-
Table 1. Baseline Characteristics of Patients
Patient characteristics n=13
Age (yr)
    Median (range)       69 (50-84)
Sex, no (%)
    Male   4 (31)
    Female   9 (69)
ECOG performance status, no (%)
    0 1 (7)
    1 11 (86)
    2 1 (7)
Stage of primary tumor*, no (%)
    T4a   6 (46)
    T4b   7 (54)
Nodal stage*, no (%)
    N0 0 (0)
    N1a   2 (15)
    N1b 11 (85)
Overall stage of disease*, no (%)
    IVa   5 (39)
    IVb   2 (15)
    IVc   6 (46)
Size of tumor       9 cm (3 -12 cm)
Distant metastasis, no (%)
    Mediastinum   6 (85)
    Lung   3 (23)
    Bone   2 (28)
    Brain   1 (14)
Treatment modality
    Doxorubicin-based definitive CCRT 5
    Surgery†
       R0 resection 2
       R1 resection  2
       R2 resection 4
ECOG, Eastern Cooperative Oncology Group; CCRT, concurrent chemora-
diotherapy.
*Tumor and nodal disease extent based on the 6th edition of the Ameri-
can Joint Committee Cancer Staging Manual.
†Surgery was followed by postoperative RT or CCRT.
Fig. 1. Overall survival (black line) and progression-free survival (dotted 
line) in patients with anaplastic thyroid carcinoma. OS, overall surrival; 
PFS, progression-free survival.
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secutive patients with ATC treated with surgery, hyperfrac-
tionated radiotherapy, and chemotherapy. The overall sur-
vival was poor with only 9% of patients surviving 2 years 
after treatment. De Crevoisier, et al.16 treated 30 patients 
with combined modality therapy, resulting in 1-year surviv-
al of 46% and a 3-year survival of 27%, which was slightly 
better outcome than most other studies. Thus, a new combi-
nation therapy is needed to improve patient survival. Che-
motherapy has changed from monotherapy with doxorubi-
cin to polychemotherapy based on newer agents such as 
paclitaxel. Radiotherapy has evolved from postoperative 
treatment to preoperative treatment, administering higher 
doses, using hyperfractionating, and accelerating dose 
schedules. There is not yet universal protocol for the treat-
ment of ATC. 
CCRT was used for most of our patients in a definitive or 
postoperative setting. This regimen is known to be effective 
for relief of symptoms arising from a large tumor mass. 
This is certainly important in a disease that often causes 
death by suffocation. ATC is highly aggressive, and  resec-
tion of all macroscopic disease is usually not feasible at the 
time of diagnosis. However, if tumors can be managed by 
aggressive surgery with preservation of organ function, sur-
gery plus adjuvant chemotherapy and radiotherapy may be 
the best option for now. 
It is imperative to develop innovative strategies beyond 
the conventional methods to tackle this lethal disease. A re-
cent study by Troch, et al.17 showed high efficacy of con-
comitant treatment with docetaxel and radiation. To exam-
ine a high rate of p53 mutation in ATC, they performed a 
retrospective analysis of six patients with ATC using docetax-
el and external beam radiation. The results were remarkable 
with four patients achieving complete remission, and two 
ceived gamma knife radio surgery due to brain metastasis 
before CCRT. One patient discontinued treatment due to 
early disease progression, and another patient died of aspi-
ration pneumonia during CCRT. After CCRT, only one pa-
tient’s condition remained stable, and rapid disease progres-
sion was observed in the other four patients. Side effects 
occurred in all patients during definitive doxorubicin-based 
CCRT. Two patients experienced grade 3 and 4 hematolog-
ic toxicity, respectively. Most nonhematologic toxicities were 
easily manageable, with mucositis and esophagitis being 
the two most common adverse events: grade 1 mucositis in 
two patients and grade 1 esophagitis in 4 patients. One pa-
tient developed grade 3 mucositis accompanied by grade 2 
neutropenia. These events required hospitalization for par-
enteral nutrition and fluid replacement. Two patients devel-
oped aspiration pneumonia during CCRT, requiring paren-
teral antibiotics, and one eventually died from respiratory 
distress. The main side effect of radiotherapy was radiation 
dermatitis, and acute reactions were mainly confined to the 
irradiated fields. The irradiated skin showed various de-
grees of erythema with hyperpigmentation, and a few pa-
tients developed moist skin desquamation toward the end 
of the treatment. All acute reactions had completely subsid-
ed 3 to 4 weeks after the completion of the treatment. 
DISCUSSION
ATC typically concerns elderly patients, and many patients 
have distant metastases at the time of diagnosis.14 Due to its 
rarity and heterogeneity, it is difficult to draw conclusion 
for definitive treatment strategies. 
Tennvall, et al.15 reported treatment outcome of 55 con-
Table 2. Treatment Outcome of 5 Patients Treated with Definitive Doxorubicin-Based CCRT
No. Age Sex
Local tumor 
mass
Stage
Radiation 
dose (Gy)
Total dose of 
doxorubicin 
received during 
CCRT (mg/m2)
Response 
to CCRT
Overall 
survival 
(months)
Clinical status 
(cause of death)
1 82 F    4×3.3 cm T4bN1bM1 64 52.8 SD 44+ Alive, NED
2 71 F    5×5.7 cm T4bN1bM0 10   9.5   NE* 3
Dead 
(aspiration pneumonia)
3 66 F 3.1×1.5 cm T4aN0M1 57 40.7  PD†    3.8
Dead 
(disease progression )
4 54 F   9×10 cm T4bN1aM0 45 60.3 PD    3.3
Dead 
(disease progression)
5 50 M 5×3 cm T4bN1bM1 65 50.5 PD   3+ Alive
SD, stable disease; PD, progressive; NED, no evidence of disease; NE, non-evaluable; CCRT, concurrent chemoradiotherapy.
*Non-evaluable due to death before follow up imaging study.
†This patient experienced rapid disease progression before completion of CCRT.
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patients partial response. This suggests that a novel thera-
peutic approach is strongly warranted.     
Molecular targets for ATC treatment are under develop-
ment,18 and Epidermal growth factor receptor (EGFR) has 
been extensively studied as a possible target. Abnormal 
EGFR activation leads to EGFR mRNA and/or protein over-
expression, which leads to cancer development and pro-
gression. Aberrant EGFR signaling leads to cellular prolif-
eration, angiogenesis, and cancer invasion and metastasis.19 
Kim, et al.20 recently reported the antiproliferative effects of 
cetuximab and irinotecan in an orthotopic anaplastic thy-
roid cancer mouse xenograft model. They demonstrated 
that cetuximab and irinotecan synergistically interact to in-
hibit the growth of orthotic anaplastic thyroid carcinoma xe-
nografts and result in 93% tumor growth inhibition. BRAF 
mutation was found to be associated with proliferation of 
thyroid carcinoma cells. Thus, suppression of BRAF might 
have a therapeutic potential, and BRAF mutation can be 
used as a prognostic factor.21 Antonelli, et al.22 recently at-
tempted to test in vitro sensitivity of thyroid cancer cells 
obtaining by fine needle aspiration (FNA) to chemothera-
peutic agents. FNA is relatively simple and easy, and testing 
the chemosensitivity of cells obtained by FNA minimizes 
unnecessary surgical procedures and administration of inef-
fective chemotherapeutic agents. 
In summary, ATC is known to have a poor prognosis due 
to its aggressive and rapid metastasis. The treatment of ATC 
with targeted therapeutics requires further clinical studies. 
Developing combinations of targeted therapies involving 
multicenter clinical trial will be helpful to optimize treat-
ment plan in the future. Moreover, prospective investiga-
tions in a multicenter clinical trial setting are needed to elu-
cidate an effective mode of treatment.
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